Key Drivers
- High Gross Margin
- Cash Flow Reversal
- Negative Equity
AIAI Summary
BCRX is now best viewed as a commercial rare-disease story anchored by ORLADEYO rather than a broad biotech R&D platform, but the investment still hinges on proving consistent free cash flow and avoiding balance-sheet strain because growth is too concentrated to absorb a slowdown.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Gross Margin
- •Cash Flow Reversal
- •Negative Equity
BCRX finished 2025 with strong margins and liquidity, but the latest quarter flipped to deep losses, negative cash flow, and a more leveraged negative-equity balance sheet.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows trend
- •Breakout support
- •$10 ceiling
BCRX has trended higher over the last month, holding above the $9.10–$9.31 breakout zone and near $9.55 support, but repeated stalls at $10.00 suggest upside still needs a clean catalyst.
Sharp drop from $10.00 to $9.55 points to short-term profit-taking and volatility
Sentiment & News
Key News Insights:
- •ORLADEYO growth
- •R&D restructuring
- •External innovation
BioCryst is reinforcing ORLADEYO-led HAE growth while streamlining R&D by shutting internal discovery and shifting to external innovation and partnerships.
The news is modestly positive for BioCryst as it highlights durable commercial momentum and a leaner operating model, though pipeline expansion now depends more on partnerships
Similar Companies in Healthcare
Other companies in the same sector with AI ratings